WallStreetZenWallStreetZen

NASDAQ: AVIR
Atea Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AVIR

Based on 1 analyst offering 12 month price targets for Atea Pharmaceuticals Inc

Min Forecast
$6.00+63.93%
Avg Forecast
$6.00+63.93%
Max Forecast
$6.00+63.93%

Should I buy or sell AVIR stock?

Based on 1 analyst offering ratings for Atea Pharmaceuticals Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although AVIR's forecast from analysts indicates a "Hold", our proven Zen Rating quant model rates AVIR as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their AVIR stock forecasts and price targets.

AVIR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-11

1 of 1

Forecast return on equity

Is AVIR forecast to generate an efficient return?

Company
-29.46%
Industry
69.22%
Market
-18.45%
AVIR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AVIR forecast to generate an efficient return on assets?

Company
-27.52%
Industry
22.77%
AVIR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AVIR earnings per share forecast

What is AVIR's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$1.79
Avg 2 year Forecast
-$1.79
Avg 3 year Forecast
-$1.42

AVIR revenue forecast

What is AVIR's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$17.2M
Avg 2 year Forecast
$60.9M

AVIR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AVIR$3.66$6.00+63.93%Hold
CADL$5.71$22.33+291.12%Strong Buy
FDMT$6.74$35.33+424.23%Strong Buy
DMAC$6.00$12.33+105.55%Strong Buy
LRMR$3.72$17.00+356.99%Buy
View Top Biotech Stocks

Atea Pharmaceuticals Stock Forecast FAQ

Is Atea Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: AVIR) stock is to Hold AVIR stock.

Out of 1 analyst, 0 (0%) are recommending AVIR as a Strong Buy, 0 (0%) are recommending AVIR as a Buy, 1 (100%) are recommending AVIR as a Hold, 0 (0%) are recommending AVIR as a Sell, and 0 (0%) are recommending AVIR as a Strong Sell.

If you're new to stock investing, here's how to buy Atea Pharmaceuticals stock.

What is AVIR's earnings growth forecast for 2025-2027?

(NASDAQ: AVIR) Atea Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 6.07%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.74%.

Atea Pharmaceuticals's earnings in 2025 is -$139,488,000.On average, 2 Wall Street analysts forecast AVIR's earnings for 2025 to be -$152,759,363, with the lowest AVIR earnings forecast at -$158,322,029, and the highest AVIR earnings forecast at -$147,196,697. On average, 2 Wall Street analysts forecast AVIR's earnings for 2026 to be -$153,187,260, with the lowest AVIR earnings forecast at -$160,033,618, and the highest AVIR earnings forecast at -$146,340,902.

In 2027, AVIR is forecast to generate -$121,094,957 in earnings, with the lowest earnings forecast at -$144,629,313 and the highest earnings forecast at -$97,560,602.

What is AVIR's revenue growth forecast for 2026-2027?

(NASDAQ: AVIR) Atea Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 226.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.76%.

Atea Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast AVIR's revenue for 2026 to be $1,473,678,560, with the lowest AVIR revenue forecast at $1,473,678,560, and the highest AVIR revenue forecast at $1,473,678,560.

In 2027, AVIR is forecast to generate $5,210,763,074 in revenue, with the lowest revenue forecast at $5,210,763,074 and the highest revenue forecast at $5,210,763,074.

What is AVIR's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: AVIR) forecast ROA is -27.52%, which is lower than the forecast US Biotechnology industry average of 22.77%.

What is AVIR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year AVIR price target, the average AVIR price target is $6.00, with the highest AVIR stock price forecast at $6.00 and the lowest AVIR stock price forecast at $6.00.

The Wall Street analyst predicted that Atea Pharmaceuticals's share price could reach $6.00 by Apr 11, 2026. The average Atea Pharmaceuticals stock price prediction forecasts a potential upside of 63.93% from the current AVIR share price of $3.66.

What is AVIR's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: AVIR) Atea Pharmaceuticals's current Earnings Per Share (EPS) is -$1.65. On average, analysts forecast that AVIR's EPS will be -$1.79 for 2025, with the lowest EPS forecast at -$1.85, and the highest EPS forecast at -$1.72. On average, analysts forecast that AVIR's EPS will be -$1.79 for 2026, with the lowest EPS forecast at -$1.87, and the highest EPS forecast at -$1.71. In 2027, AVIR's EPS is forecast to hit -$1.42 (min: -$1.69, max: -$1.14).

What is AVIR's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: AVIR) forecast ROE is -29.46%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.